Fleur Mauritz Receives ESTRO 2026 Young Researcher Award for Breast Cancer Radiotherapy De-Escalation Study
ESTRO shared on X: “ESTRO26 Young Researcher Award 10-yr RAPCHEM study proves we can safely de-escalate radiotherapy for cT1-2N1 Breast Cancer after chemo. By tailoring RT to nodal response, patients…
Read the full articleYou might also wanna read
Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy
Methylation-based ctDNA monitoring in 57 patients closely reflects outcomes in ER+, HER2- metastatic breast cancer during CDK4/6 inhibitor t
Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer
Conditions : Breast Cancer (Triple Negative Breast Cancer (TNBC)) Interventions : Other: Non interventional study Sponsors : Assistance Publ
<![CDATA[20 On the Upswing: A Retrospective Cohort Study Evaluating Neoadjuvant Chemotherapy Response in Metaplastic Breast Cancer Patients]]>
El V Oncocongreso de Alicante abordará los últimos avances en el tratamiento contra el cáncer
El evento tendrá lugar el 28 de noviembre para poner en el centro del debate la atención multidisciplinar a pacientes oncológicos
El V Oncocongreso de Alicante abordará los últimos avances en el tratamiento contra el cáncer
El evento tendrá lugar el 28 de noviembre para poner en el centro del debate la atención multidisciplinar a pacientes oncológicos
Breast Cancer Treatment Strategies: AI ± CDK4/6 Inhibitors, Biomarkers, and ESR1 Mutations
Did you know that the prevalence of acquired ESR1 mutations increases after exposure to endocrine therapy?
mdsc.pe·17d ago
Estudo vê economia com teste genômico no câncer de mama
Um estudo brasileiro apresentado na edição deste ano do congresso da American Society of Clinical Oncology (ASCO), principal evento mundial
Comments
Sign in to join the conversation.
No comments yet. Be the first.